Antihypertensive Mechanisms of Minocycline in Resistant Hypertension

Description

The goal of this clinical trial is to learn about the mechanisms by which minocycline effect blood pressure in individuals with treatment-resistant hypertension. The main questions it aims to answer are: * To what extent does minocycline lower blood pressure and are these effects different across races? * Are such blood pressure effects mediated through changes in gut microbiota, gut leakiness, systemic inflammation, neuroinflammation, or some combination of these? Participants will be randomly assigned to treatment with minocycline or placebo, treated daily for 3 months, to evaluate these questions.

Conditions

Hypertension, Resistant to Conventional Therapy

Talk to us

Study Overview

On this page

Study Details

Study overview

The goal of this clinical trial is to learn about the mechanisms by which minocycline effect blood pressure in individuals with treatment-resistant hypertension. The main questions it aims to answer are: * To what extent does minocycline lower blood pressure and are these effects different across races? * Are such blood pressure effects mediated through changes in gut microbiota, gut leakiness, systemic inflammation, neuroinflammation, or some combination of these? Participants will be randomly assigned to treatment with minocycline or placebo, treated daily for 3 months, to evaluate these questions.

Antihypertensive Mechanisms of Minocycline in Resistant Hypertension: Role of the Gut Microbiota-brain-immune Axis

Antihypertensive Mechanisms of Minocycline in Resistant Hypertension

Condition
Hypertension, Resistant to Conventional Therapy
Intervention / Treatment

-

Contacts and Locations

Gainesville

UF Health Cardiology - Heart & Vascular Hospital, Gainesville, Florida, United States, 32610

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age ≥18 years
  • * Self-identify as White or African American
  • * Uncontrolled TRH, defined as uncontrolled blood pressure (mean 24-hour ambulatory systolic BP ≥125 mm Hg or diastolic BP ≥80 mm Hg) while being adherent to a stable (no changes in ≥30 days prior) antihypertensive regimen of 3 or more drugs, including an adequately dosed thiazide or thiazide-like diuretic (hydrochlorothiazide ≥25 mg/day or equivalent)
  • * The participant agrees to have all study procedures performed
  • * Known hypersensitivity or contraindication to minocycline or other tetracyclines
  • * Recent (≤3 months prior), ongoing, or expected use of oral antibiotics
  • * Estimated glomerular filtration rate (eGFR) of \<45mL/min/1.73m2, using the MDRD equation
  • * Known secondary hypertension
  • * History of antihypertensive crisis, defined as any in-patient hospitalizations for antihypertensive crisis/emergency within the past year
  • * History of orthostatic hypotension, defined as two or more episode(s) of orthostatic hypotension (reduction of SBP of \>20 mm Hg or DBP of \>10 mm Hg within 3 minutes of standing) in the past year
  • * History of myocardial infarction, unstable angina, syncope, or cerebrovascular accident in prior 6 months
  • * Evidence of alcoholism or drug abuse
  • * Severe comorbid conditions (i.e., neoplasms or HIV positive or AIDS)
  • * Ongoing or expected use of significant BP-interfering medications (excepting oral contraceptives)
  • * Current pregnancy or anticipated pregnancy during the study.

Ages Eligible for Study

18 Years to 85 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Florida,

Steven M Smith, PharmD, MPH, PRINCIPAL_INVESTIGATOR, University of Florida

Study Record Dates

2028-07